Denali Therapeutics Inc.
DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also developsā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$21.09
Price-1.45%
-$0.31
1Y
Price
Market Cap
$3.347b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-3440.2%
EBITDA Margin-3539.2%
Net Profit Margin-2713.8%
Free Cash Flow Margin-3440.2%
EBITDA Margin-3539.2%
Net Profit Margin-2713.8%
Free Cash Flow MarginRevenue
$3.604m
-
1y CAGR-33.3%
3y CAGR+26.2%
5y CAGREarnings
-$511.451m
+0.2%
1y CAGR-70.7%
3y CAGR-39.2%
5y CAGREPS
-$2.84
+4.4%
1y CAGR-51.2%
3y CAGR-23.6%
5y CAGRBook Value
$835.178m
$1.158b
Assets$322.777m
Liabilities$27.505m
DebtDebt to Assets
2.4%
-0.1x
Debt to EBITDAFree Cash Flow
-$437.457m
-3.6%
1y CAGR-5.9%
3y CAGR-14.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company